The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Progress in ovarian cancer treatment lags behind other tumor types. With diagnosis usually
at an advanced stage, there is a high demand for reliable prognostic biomarkers capable of …

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Ovarian cancer (OC) is an aggressive gynecological tumor usually diagnosed with
widespread metastases and ascites. Here, we depicted a single-cell landscape of the OC …

Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …

Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Background Although most patients with epithelial ovarian cancer respond to frontline
platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 …

Purpose: The heterogeneity of high-grade serous ovarian cancer (HGSOC) is not well
studied, which severely hinders clinical treatment of HGSOC. Thus, it is necessary to …